AM Squared Ltd Makes New $422,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

AM Squared Ltd acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 6,300 shares of the medical device company’s stock, valued at approximately $422,000. DexCom makes up approximately 0.9% of AM Squared Ltd’s holdings, making the stock its 10th largest position.

Other institutional investors and hedge funds have also made changes to their positions in the company. Capital Insight Partners LLC lifted its holdings in shares of DexCom by 2.5% in the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after acquiring an additional 90 shares during the last quarter. HM Payson & Co. lifted its holdings in shares of DexCom by 6.0% in the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after acquiring an additional 100 shares during the last quarter. Clear Creek Financial Management LLC lifted its holdings in shares of DexCom by 4.2% in the 2nd quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after acquiring an additional 120 shares during the last quarter. SeaCrest Wealth Management LLC lifted its holdings in shares of DexCom by 3.6% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock worth $501,000 after acquiring an additional 152 shares during the last quarter. Finally, Securian Asset Management Inc. lifted its holdings in shares of DexCom by 0.7% in the 2nd quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock worth $2,593,000 after acquiring an additional 161 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Up 1.6 %

Shares of NASDAQ:DXCM opened at $75.88 on Friday. The stock has a market cap of $29.64 billion, a P/E ratio of 45.44, a P/E/G ratio of 2.33 and a beta of 1.17. The firm has a fifty day moving average price of $70.03 and a 200 day moving average price of $91.42. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DXCM. Piper Sandler restated an “overweight” rating and issued a $90.00 target price on shares of DexCom in a report on Monday, August 26th. Oppenheimer decreased their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Morgan Stanley decreased their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a report on Friday, July 26th. JPMorgan Chase & Co. lifted their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Finally, BTIG Research decreased their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $104.59.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.